AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21426620 — intervention group
Group type: COMPARATOR
Intervention: Control group (children did not take part in any special linguistic activities after story readings)
Number of subjects: 100
Study 19784813 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis (gene and cell therapy)
Number of subjects: 543
Study 19784813 — intervention group
Group type: COMPARATOR
Intervention: Gene therapy
Number of subjects: 543
Study 17762338 — intervention group
Group type: COMPARATOR
Intervention: Referral patterns for advanced lung cancer
Number of subjects: 672
Study 17762338 — intervention group
Group type: COMPARATOR
Intervention: Knowledge about chemotherapy benefits in advanced cancer
Number of subjects: 672
Study 17762338 — intervention group
Group type: COMPARATOR
Intervention: Referral for further therapy
Number of subjects: 672
Study 15165921 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 15165921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11813739 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal advice plus written prescription (green prescription)
Number of subjects: 49
Study 11813739 — intervention group
Group type: COMPARATOR
Intervention: Verbal advice only
Number of subjects: 49
Study 10676820 — intervention group
Group type: EXPERIMENTAL
Intervention: lesopitron 4‐80 mg/d
Number of subjects: 161
Study 10676820 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 2‐4 mg/d
Number of subjects: 161
Study 10676820 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 161
Study 9094885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (diet, alcohol, smoking, and weight loss)
Number of subjects: 94
Study 9094885 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intakes of monounsaturated fat relative to saturated fat and stearic acid (18:0) consumption
Number of subjects: 94
Study 9094885 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications reducing body mass index by 5 kg/m2, quitting a 10 cigarette/d smoking habit, and reducing dietary cholesterol intake by 100 mg/d
Number of subjects: 94
Study 9094885 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 94
Study 9094885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle modification
Number of subjects: 94
Study 8244194 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-nystatin vagitories
Number of subjects: 66
Study 8244194 — intervention group
Group type: COMPARATOR
Intervention: Placebo vagitories
Number of subjects: 66
Study 3857148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor‐Protector
Number of subjects: 787
Study 3857148 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat
Number of subjects: 787
Study 3857148 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 787
Study 30819379 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 1767
Study 30819379 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 1767
Study 30566701 — intervention group
Group type: EXPERIMENTAL
Intervention: DAVS (Digitally Assisted Vitreoretinal System)
Number of subjects: 40
Study 30566701 — intervention group
Group type: COMPARATOR
Intervention: AM (Analog Microscope)
Number of subjects: 40
Study 27688160 — intervention group
Group type: EXPERIMENTAL
Intervention: Disrupted stimulation
Number of subjects: 12
Study 27688160 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking mode
Number of subjects: 12
Study 27688160 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 12
Study 24882909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion to 'sleep deeper'
Number of subjects: 70
Study 24882909 — intervention group
Group type: COMPARATOR
Intervention: Control tape
Number of subjects: 70
Study 22897460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 150/5mg for 1 week, then up-titration to 300/10 mg for 7 weeks
Number of subjects: 485
Study 22897460 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg for 1 week, then up-titration to 10 mg for 7 weeks
Number of subjects: 485
Study 22897460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine combination therapy
Number of subjects: 485
Study 22897460 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine monotherapy
Number of subjects: 485
Study 21029826 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 168
Study 21029826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 18574751 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mug inhaled procaterol
Number of subjects: 19
Study 18574751 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 19
Study 15909359 — intervention group
Group type: EXPERIMENTAL
Intervention: School lunch + home economics intervention (SL + HE)
Number of subjects: 228
Study 15909359 — intervention group
Group type: EXPERIMENTAL
Intervention: School lunch intervention (SL)
Number of subjects: 228
Study 15909359 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 11839447 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg gum
Number of subjects: 84
Study 11839447 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg gum
Number of subjects: 84
Study 11839447 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg gum
Number of subjects: 84
Study 11839447 — intervention group
Group type: COMPARATOR
Intervention: 50 mg capsule
Number of subjects: 84
Study 11839447 — intervention group
Group type: COMPARATOR
Intervention: 100 mg capsule
Number of subjects: 84
Study 11839447 — intervention group
Group type: COMPARATOR
Intervention: 200 mg capsule
Number of subjects: 84
Study 11839447 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg gum (normalized to total drug released)
Number of subjects: 84
Study 11839447 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg gum (normalized to total drug released)
Number of subjects: 84
Study 11839447 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg gum (normalized to total drug released)
Number of subjects: 84
Study 10506315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 150 microg/kg
Number of subjects: 89
Study 10506315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 200 microg/kg
Number of subjects: 89
Study 10506315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 250 microg/kg
Number of subjects: 89
Study 10506315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 300 microg/kg
Number of subjects: 89
Study 10506315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 450 microg/kg
Number of subjects: 89
Study 10506315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 600 microg/kg
Number of subjects: 89
Study 10506315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (all doses)
Number of subjects: 89
Study 7672088 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with chlorambucil (CLB)
Number of subjects: 148
Study 7672088 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy until progression
Number of subjects: 148
Study 7672088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study 2178298 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP antagonist [d(CH2)5 Tyr(Me)AVP] 5 micrograms/kg
Number of subjects: 6
Study 2178298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 6
Study 2178298 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP antagonist [d(CH2)5 Tyr(Me)AVP] 10 micrograms/kg
Number of subjects: 6
Study 2178298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) during insulin-induced hypoglycemia
Number of subjects: 6
Study 31810437 — intervention group
Group type: COMPARATOR
Intervention: Cannabidiol (CBD) - 100 mg/mL formulation, dose range 50 mg to 600 mg per day, titrated over 2 weeks followed by a 2-week assessment period.
Number of subjects: 0
Study 31810437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28449630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 90
Study 28449630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.2 MAC
Number of subjects: 90
Study 28449630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.4 MAC
Number of subjects: 90
Study 28449630 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, assumed to be rocuronium at 0.45 mg/kg)
Number of subjects: 90
Study 28449630 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 90
Study 26084697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g daily for 6 days)
Number of subjects: 14
Study 26084697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 26084697 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing a mixture of 60% O2/balance N2
Number of subjects: 14
Study 26084697 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing air (∼222 kPa N2/59 kPa O2)
Number of subjects: 14
Study 23578427 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft (44 patients, using autogeneic hamstring tendons)
Number of subjects: 86
Study 23578427 — intervention group
Group type: COMPARATOR
Intervention: Allograft (42 patients, using allogenic lower extremity tendons)
Number of subjects: 86
Study 21330651 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented communication interventions with a speech-generating device
Number of subjects: 53
Study 21330651 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken intervention
Number of subjects: 53
Study 21330651 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall child outcomes
Number of subjects: 53
Study 19743984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-enriched drinking yogurt
Number of subjects: 30
Study 19743984 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular drinking yogurt
Number of subjects: 30
Study 19743984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh banana
Number of subjects: 30
Study 19743984 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain crackers
Number of subjects: 30
Study 19743984 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 30
Study 17347187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy (n=36)
Number of subjects: 70
Study 17347187 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list, n=34)
Number of subjects: 70
Study 16137015 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 68
Study 16137015 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 68
Study 11246300 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 257
Study 11246300 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 257
Study 9519350 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 100
Study 9519350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7846463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin administered at 1200 hours
Number of subjects: 18
Study 7846463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin administered at 1700 hours
Number of subjects: 18
Study 7846463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin administered at 1900 hours
Number of subjects: 18
Study 7846463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin administered at 2100 hours
Number of subjects: 18
Study 7846463 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 1200, 1700, 1900, and 2100 hours
Number of subjects: 18
Study 3133216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytostatic bladder instillation (mitomycin C and adriamycin)
Number of subjects: 0
Study 3133216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of long-term and short-term instillation protocols
Number of subjects: 0
Study 3133216 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 0
Study 3133216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 0
Study 3133216 — intervention group
Group type: COMPARATOR
Intervention: Short-term prophylaxis
Number of subjects: 0
Study 3133216 — intervention group
Group type: COMPARATOR
Intervention: Long-term prophylaxis
Number of subjects: 0
Study 31527670 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebos
Number of subjects: 58
Study 31527670 — intervention group
Group type: COMPARATOR
Intervention: No pills (control group)
Number of subjects: 58
Study 27866000 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 90
Study 27866000 — intervention group
Group type: EXPERIMENTAL
Intervention: QMix
Number of subjects: 90
Study 27866000 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% grape seed extract
Number of subjects: 90
Study 27866000 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with optical fiber
Number of subjects: 90
Study 27866000 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy without optical fiber
Number of subjects: 90
Study 27866000 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 90
Study 27866000 — intervention group
Group type: EXPERIMENTAL
Intervention: Final decontamination protocols (all groups)
Number of subjects: 90
Study 24687249 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek™ Silorane
Number of subjects: 72
Study 24687249 — intervention group
Group type: COMPARATOR
Intervention: Ceram•X™
Number of subjects: 72
Study 24152748 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplements
Number of subjects: 201
Study 24152748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 22120092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg/day for 7 days
Number of subjects: 110
Study 22120092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 18719791 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical activity (1-hour sessions, 3 times a week for 6 months)
Number of subjects: 45
Study 18719791 — intervention group
Group type: COMPARATOR
Intervention: Control Group (oriented to non-pharmacological treatment)
Number of subjects: 45
Study 16794490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 12
Study 16794490 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 12
Study 14501741 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 440
Study 14501741 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 440
Study 14501741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 10750263 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) treatment
Number of subjects: 0
Study 9108975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Day Acuvue lens
Number of subjects: 48
Study 9108975 — intervention group
Group type: COMPARATOR
Intervention: Medalist lens
Number of subjects: 48
Study 9108975 — intervention group
Group type: COMPARATOR
Intervention: Regular Acuvue lens
Number of subjects: 48
Study 8267478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 18
Study 2931063 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac (200 mg twice daily)
Number of subjects: 24
Study 2931063 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 29218791 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-contingent video games for low-cost in-home training of attention and eye movement, over a duration of 8 weeks.
Number of subjects: 8
Study 28052576 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL/day ONS (10.1 KJ and 0.096 g protein per mL) and dietary advice
Number of subjects: 101
Study 28052576 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 101
Study 28052576 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL/day ONS and dietary advice
Number of subjects: 101
Study 26168834 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT) with LiDCO rapid system
Number of subjects: 52
Study 26168834 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine fluid therapy)
Number of subjects: 52
Study 23329469 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-based epilepsy education programme (Mobile Epilepsy Educational System - MEES)
Number of subjects: 144
Study 23329469 — intervention group
Group type: COMPARATOR
Intervention: Printed epilepsy educational module
Number of subjects: 144
Study 21266159 — intervention group
Group type: EXPERIMENTAL
Intervention: Automation-assisted reading of cervical cytology slides paired with manual reading
Number of subjects: 0
Study 21266159 — intervention group
Group type: COMPARATOR
Intervention: Manual reading of cervical cytology slides
Number of subjects: 0
Study 20633415 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 11
Study 20633415 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS)
Number of subjects: 11
Study 20633415 — intervention group
Group type: COMPARATOR
Intervention: sham TBS
Number of subjects: 11
Study 16571907 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with Williams syndrome (WS)
Number of subjects: 28
Study 16571907 — intervention group
Group type: COMPARATOR
Intervention: Participants with Down syndrome (DS)
Number of subjects: 28
Study 16571907 — intervention group
Group type: COMPARATOR
Intervention: Participants with undifferentiated developmental delays
Number of subjects: 28
Study 16571907 — intervention group
Group type: COMPARATOR
Intervention: Participants from the general population
Number of subjects: 28
Study 15650471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress-reduction program (8 weeks, 2 hours per week)
Number of subjects: 18
Study 15650471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study 11369828 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril alone or in combination with verapamil
Number of subjects: 22
Study 11369828 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker (atenolol)
Number of subjects: 22
Study 11369828 — intervention group
Group type: COMPARATOR
Intervention: Non-dihydropyridine calcium channel blocker (verapamil)
Number of subjects: 22
Study 11369828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of verapamil+trandolapril at half the dose
Number of subjects: 22
Study 9161390 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 180
Study 9161390 — intervention group
Group type: COMPARATOR
Intervention: Nonprotocol use of antibiotics
Number of subjects: 180
Study 9161390 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin sodium for 4 weeks
Number of subjects: 180
Study 9161390 — intervention group
Group type: COMPARATOR
Intervention: Sterile severe acute pancreatitis
Number of subjects: 180
Study 9161390 — intervention group
Group type: COMPARATOR
Intervention: Infected patients
Number of subjects: 180
Study 9161390 — intervention group
Group type: COMPARATOR
Intervention: Infection within the first 4 weeks
Number of subjects: 180
Study 9161390 — intervention group
Group type: COMPARATOR
Intervention: Infection after 4 weeks
Number of subjects: 180
Study 9161390 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin protocol for infections after 4 weeks
Number of subjects: 180
Study 9161390 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality rates
Number of subjects: 180
Study 8233987 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch condition (children patted on the upper arm or shoulder during examination)
Number of subjects: 38
Study 8233987 — intervention group
Group type: COMPARATOR
Intervention: No-touch control condition (children received only verbal reassurance without contact)
Number of subjects: 38
Study 8233987 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch condition
Number of subjects: 38
Study 8233987 — intervention group
Group type: COMPARATOR
Intervention: No-touch control condition
Number of subjects: 38
Study 3304371 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (1.5‐15 mg/hr)
Number of subjects: 100
Study 3304371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30161166 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 5680
Study 30161166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 5680
Study 30161166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 5680
Study 27555168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.9 mg/kg) administered in the MR group (35 patients)
Number of subjects: 70
Study 27555168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (MR group)
Number of subjects: 70
Study 27555168 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group; 35 patients)
Number of subjects: 70
Study 27555168 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 70
Study 25496296 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First treatment model
Number of subjects: 231
Study 25496296 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative component (in-depth interviews)
Number of subjects: 231
Study 22098540 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention with nursing presence
Number of subjects: 34
Study 22098540 — intervention group
Group type: COMPARATOR
Intervention: Recorded music
Number of subjects: 34
Study 20105410 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician advice intervention consisting of two 15-minute counseling visits and two follow-up phone calls using motivational interviewing, contracting, diary cards, and take-home exercises
Number of subjects: 996
Study 20105410 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 996